Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents

Area of Science:

• Microbiology
• Nanotechnology
• Pharmacology

Background:

• Staphylococcus strains exhibit high resistance to penicillin, with Methicillin-resistant Staphylococcus aureus (MRSA) emerging in 1961.
• Vancomycin, introduced in 1980, became a primary treatment for MRSA but is challenged by Vancomycin-resistant Staphylococcus aureus (VRSA), first identified in 2002.
• Vancomycin functions by inhibiting peptidoglycan biosynthesis and the assembly of NAM-NAG-polypeptide chains.

Purpose of the Study:

• To investigate the efficacy of folic acid-tagged chitosan nanoparticles as a delivery system for vancomycin against VRSA.
• To evaluate the biocompatibility and biodegradability of these novel nanocarriers.
• To assess the enhanced drug action of vancomycin delivered via nanoconjugates.

Main Methods:

• Folic acid-tagged chitosan nanoparticles were synthesized to encapsulate vancomycin.
• The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of vancomycin-loaded nanoparticles were determined.
• Studies focused on the transport of vancomycin across epithelial surfaces and its bactericidal effect on VRSA.

Main Results:

• Vancomycin-loaded nanoconjugates demonstrated enhanced transport across epithelial surfaces.
• Tolerance values indicated that nanoparticle-delivered vancomycin is highly effective against VRSA.
• The nanoconjugate formulation exhibited a strong bactericidal effect on VRSA.

Conclusions:

• Folic acid-tagged chitosan nanoparticles serve as effective Trojan horses for vancomycin delivery into bacterial cells.
• These biocompatible and biodegradable nanocarriers significantly enhance vancomycin's efficacy against VRSA.
• The nanodelivery system presents a promising approach to overcome vancomycin resistance in Staphylococcus aureus infections.